Asarfi Hospital Ltd

Q4 FY26Healthcare Services

ASARFI Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹212

Market cap₹497 Cr

P/E29.6

Published24 Jun 2026

What the Q4 FY26 call signalled

3 of 4 strong

RevenueRank 2

MarginRank 3

CapexYes

FundraiseYes

Not discussed on this call: order book.

The short version

- Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26. - Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up.

From Asarfi Hospital Ltd's Q4 FY26 earnings-call transcript · updated 24 Jun 2026.

Revenue & Sales Performance

Rank 2

Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26.
Aim to scale overall bed capacity to over 500 beds by 2028 (from current 350 beds).
Cancer hospital capacity to increase from 65 beds to 150 beds, with significant revenue growth expected from this segment.
Revenue growth driven by bed expansion, occupancy ramp-up, ARPOB (Average Revenue Per Occupied Bed) improvement, transplant services, and management contracts.
Expect organic and inorganic growth, including hospital acquisitions planned in FY27.
Bone marrow transplant facility to start contributing revenue from FY28.
Long-term plan targets INR 400 crores revenue and EBITDA margin of 23-25%.
PAT growth expected to be aligned with revenue and EBITDA growth, with a focus on cost management and improved case mix.
Confident about sustaining momentum and 50% CAGR growth over next 4-5 years.

Profitability & Margins

Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up.
The company aims to scale bed capacity to over 500 beds by 2028 and generate around INR 400 crores in revenue.
EBITDA margin is expected to improve from 20% in FY26 to 22-25% in FY27, with a focus on case mix optimization and cost management.
PAT margin guidance is 13-15% for FY27, with efforts to maintain PAT growth consistent with revenue growth.
Expansion drivers include cancer hospital growth (increasing from 65 to 150 beds), bone marrow transplant facility commencement (FY28 contribution), and inorganic growth via hospital acquisitions.
Management intends to achieve 50% CAGR growth over the next 4-5 years, maintaining strong profitability and operational discipline.
Internal accruals are expected to fund growth, with limited reliance on debt unless major capex opportunities arise.

See what Asarfi Hospital Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Healthcare Management Research Institute under construction with expected capex of INR 8 to 10 crores in the coming fiscal year.
Additional capex of INR 2 to 3 crores planned to unlock current capacity and expand super specialty and oncology beds — total FY27 capex expected to be under INR 15 crores.
Bed expansion plan to increase cancer hospital beds from 65 to 150, with relatively low capex of INR 2 to 3 crores due to existing infrastructure.
Inorganic growth through hospital acquisition is underway, with technical issues being resolved and materialization expected within the financial year.
Potential strategic management contracts and partnerships in nearby regions are in exploration as part of growth strategy.
Main board migration process initiated after July eligibility.
Future expansions and hospital additions planned, but model still under development considering government cashless scheme constraints.

Fundraising & Capital Structure

Asarfi Hospital Limited has not currently decided to raise debt for further growth.
Growth is planned to be managed through internal accruals as of now.
However, the management remains open to taking debt if a major capital expenditure or opportunity arises.
In the recent call, it was mentioned that if any significant funding need arises, the company will inform stakeholders accordingly.
Regarding equity fundraising, no explicit mention of new equity issuance or fundraising was made during the call.
The company is focused on organic and inorganic growth, including potential acquisitions, which might require funding.
Cash holdings are currently between INR 8 crores to INR 10 crores, which provide some liquidity.
Overall, no immediate plans for fundraising but flexibility to consider debt depending on opportunities.

See what Asarfi Hospital Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not mention any details regarding current or expected order book or pending orders for Asarfi Hospital Limited. The discussion focuses primarily on: - Operational performance, bed capacity expansion - Revenue and EBITDA guidance - Government scheme reimbursements and delays - Capital expenditure plans and acquisitions - Growth outlook and strategic initiatives No specific information on order book or pending orders was disclosed in the Q4 & FY26 earnings conference call transcript.

How does Asarfi Hospital Ltd rank vs peers in Healthcare Services?

Pro feature

ThisAsarfi Hospital Ltd

Rev 2Mar 3

See where Asarfi Hospital Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

Asarfi Hospital Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹45 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Asarfi Hospital Ltd's management said in earlier quarters

Others in Healthcare Services this season

Apollo Hospitals (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
Vimta Labs Ltd (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals vs Max Healthcare Institute Ltd vs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Asarfi Hospital Ltd Q1 FY27 results?

What is Asarfi Hospital Ltd share price analysis?

Asarfi Hospital Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 29.6 with a market cap of ₹497. Investors should review the full earnings analysis for detailed insights.

Is Asarfi Hospital Ltd planning capital expenditure?

- Healthcare Management Research Institute under construction with expected capex of INR 8 to 10 crores in the coming fiscal year.

Keep Asarfi Hospital Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.